Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. It
has a poor response to conventional therapy and has an extremely poor 5-year survival rate …

Pancreatic ductal metaplasia (PDM) is the transformation of potentially many type of cells in
pancreas into ductal or ductal-like cells, which eventually replace the existing differentiated …

Background The epigenetic mechanisms involved in the progression of pancreatic ductal
adenocarcinoma (PDAC) remain largely unexplored. This study aimed to identify key …

Pancreatic ductal adenocarcinoma (PDAC) has extremely poor prognosis, with a 5-year
survival rate of approximately 11%. Yes-associated protein (YAP) is a major downstream …

Background & Aims Inactivating mutations of KDM6A, a histone demethylase, were
frequently found in pancreatic ductal adenocarcinoma (PDAC). We investigated the role of …

Differentiated cells across multiple species and organs can re‐enter the cell cycle to aid in
injury‐induced tissue regeneration by a cellular program called paligenosis. Here, we show …

TP53 and ARID1A are frequently mutated across cancer but rarely in the same primary
tumor. Endometrial cancer has the highest TP53-ARID1A mutual exclusivity rate. However …

Pancreatitis is a debilitating disease involving inflammation and fibrosis of the exocrine
pancreas. Recurrent or chronic forms of pancreatitis are a significant risk factor for …

Background Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with a five-
year survival rate of approximately 10%. Genetic mutations are pivotal drivers in PDAC …

Purpose Olaparib, an inhibitor of poly-(adenosine diphosphate-ribose) polymerase (PARP),
has been shown to have anticancer benefits in patients with pancreatic cancer who have a …